Oncternal Therapeutics (ONCT) Short Interest Ratio & Short Volume → How Biden has already won 2024 (From Porter & Company) (Ad) Free ONCT Stock Alerts $8.18 -0.46 (-5.32%) (As of 05/10/2024 08:55 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Oncternal Therapeutics Short Interest DataCurrent Short Volume13,000 sharesPrevious Short Volume13,800 sharesChange Vs. Previous Month-5.80%Dollar Volume Sold Short$108,032.60Short Interest Ratio / Days to Cover1.8Last Record DateApril 30, 2024Outstanding Shares2,960,000 sharesFloat Size2,670,000 sharesShort Percent of Float0.49%Today's Trading Volume2,500 sharesAverage Trading Volume11,045 sharesToday's Volume Vs. Average23% Short Selling Oncternal Therapeutics ? Sign up to receive the latest short interest report for Oncternal Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatONCT Short Interest Over TimeONCT Days to Cover Over TimeONCT Percentage of Float Shorted Over Time Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here Oncternal Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202413,000 shares $108,032.60 -5.8%0.5%1.8 $8.31 4/15/202413,800 shares $121,440.00 -17.4%0.5%1.5 $8.80 3/31/202416,700 shares $150,300.00 +11.3%0.6%1.3 $9.00 3/15/202415,000 shares $120,300.00 -6.3%0.6%1 $8.02 2/29/202416,000 shares $148,800.00 -28.3%0.6%0.9 $9.30 2/15/202422,300 shares $200,477.00 -10.8%0.8%1.3 $8.99 Get the Latest News and Ratings for ONCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202425,000 shares $244,250.00 +25.0%0.9%1.5 $9.77 1/15/202420,000 shares $171,800.00 +52.7%0.8%1.2 $8.59 12/31/202313,100 shares $140,484.40 -94.6%0.4%0.9 $10.72 12/15/2023241,400 shares $91,732.00 -22.1%N/A1 $0.38 11/30/2023310,000 shares $114,080.00 -28.6%N/A1.7 $0.37 11/15/2023433,900 shares $140,974.11 +5.5%N/A2.9 $0.32 10/31/2023411,200 shares $139,561.28 +46.7%N/A2.5 $0.34 10/15/2023280,300 shares $82,688.50 +2.1%N/A1.7 $0.30 9/30/2023274,500 shares $82,350.00 -8.0%N/A1.4 $0.30 9/15/2023298,300 shares $104,405.00 +0.6%N/A1.4 $0.35 8/31/2023296,500 shares $88,950.00 -7.6%N/A1.2 $0.30 8/15/2023320,900 shares $120,979.30 -6.4%N/A1.2 $0.38 7/31/2023342,700 shares $126,901.81 -23.6%N/A1.3 $0.37 7/15/2023448,600 shares $205,593.38 +32.8%N/A1.7 $0.46 6/30/2023337,700 shares $116,506.50 -4.0%N/A0.9 $0.35 6/15/2023351,600 shares $140,640.00 +27.4%N/A0.6 $0.40 5/31/2023276,100 shares $78,688.50 +7.4%N/A0.5 $0.29 5/15/2023257,000 shares $75,815.00 -46.6%N/A0.5 $0.30 4/30/2023480,900 shares $147,395.85 -1.9%N/A0.9 $0.31 4/15/2023490,300 shares $153,120.69 +29.0%N/A1 $0.31 3/31/2023380,000 shares $298,300.00 -8.0%N/A0.8 $0.79 3/15/2023412,900 shares $300,426.04 +1.8%N/A1.8 $0.73 2/28/2023405,600 shares $361,632.96 -2.1%N/A1.5 $0.89 2/15/2023414,200 shares $426,626.00 -5.6%N/A1.6 $1.03 1/31/2023438,600 shares $491,232.00 -34.3%N/A1.6 $1.12 1/15/2023667,600 shares $861,204.00 -29.7%N/A2.4 $1.29 12/30/2022950,000 shares $950,000.00 +0.2%N/A3.4 $1.00 12/15/2022947,800 shares $871,976.00 +61.3%N/A3.4 $0.92 11/30/2022587,700 shares $534,865.77 -18.2%N/A2.1 $0.91 11/15/2022718,800 shares $725,988.00 +28.0%N/A2.8 $1.01 10/31/2022561,400 shares $589,470.00 -15.6%N/A1.7 $1.05 10/15/2022665,300 shares $725,177.00 -52.1%N/A1.8 $1.09 9/30/20221,390,000 shares $1.24 million +70.0%N/A3.3 $0.89 9/15/2022817,800 shares $801,525.78 +38.2%1.7%1.6 $0.98The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. ONCT Short Interest - Frequently Asked Questions What is Oncternal Therapeutics' current short interest? Short interest is the volume of Oncternal Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 13,000 shares of ONCT short. 0.49% of Oncternal Therapeutics' shares are currently sold short. Learn More on Oncternal Therapeutics' current short interest. What is a good short interest ratio for Oncternal Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ONCT shares currently have a short interest ratio of 2.0. Learn More on Oncternal Therapeutics's short interest ratio. What is a good short interest percentage for Oncternal Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.49% of Oncternal Therapeutics' floating shares are currently sold short. Is Oncternal Therapeutics' short interest increasing or decreasing? Oncternal Therapeutics saw a decrease in short interest in April. As of April 30th, there was short interest totaling 13,000 shares, a decrease of 5.8% from the previous total of 13,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Oncternal Therapeutics' float size? Oncternal Therapeutics currently has issued a total of 2,960,000 shares. Some of Oncternal Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Oncternal Therapeutics currently has a public float of 2,670,000 shares. How does Oncternal Therapeutics' short interest compare to its competitors? 0.49% of Oncternal Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Oncternal Therapeutics: Iterum Therapeutics plc (7.68%), Qilian International Holding Group Limited (0.69%), Forte Biosciences, Inc. (0.08%), Lumos Pharma, Inc. (6.09%), Biora Therapeutics, Inc. (4.52%), Lipocine Inc. (3.49%), Unity Biotechnology, Inc. (2.16%), Lisata Therapeutics, Inc. (0.22%), Acasti Pharma Inc. (0.02%), TherapeuticsMD, Inc. (0.46%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Oncternal Therapeutics stock? Short selling ONCT is an investing strategy that aims to generate trading profit from Oncternal Therapeutics as its price is falling. ONCT shares are trading down $0.46 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oncternal Therapeutics? A short squeeze for Oncternal Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ONCT, which in turn drives the price of the stock up even further. How often is Oncternal Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ONCT, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Iterum Therapeutics Short Interest Qilian International Holding Group Short Interest Forte Biosciences Short Interest Lumos Pharma Short Interest Biora Therapeutics Short Interest Lipocine Short Interest Unity Biotechnology Short Interest Lisata Therapeutics Short Interest Acasti Pharma Short Interest TherapeuticsMD Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ONCT) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss Ratings